Oric Pharmaceuticals, Inc.
Oric Pharmaceuticals, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 4, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 3.5 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 6 concluded trials, 67% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 4, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| December 15, 2026 | ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC | Trial Milestone | Phase 1 |
| June 15, 2027 | Study of ORIC-944 in Patients With Metastatic Prostate Cancer | Trial Milestone | Phase 1 |
| March 15, 2028 | A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) | Trial Milestone | Phase 3 |
Track ORIC alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ORIC in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.